Related Experiment Video
Updated: Jul 1, 2025
07:34
Enrichment of Astrocyte-Derived Extracellular Vesicles from Human Plasma
Published on: August 3, 2022
2.9K
Extracellular vesicles in Alzheimer's disease
Victor Hugo Berriel Pinho1, João Paulo Lima Daher2, Salim Kanaan2
1Universidade Federal do Rio de Janeiro, Faculdade de Medicina, Rio de Janeiro RJ, Brazil.
Arquivos De Neuro-Psiquiatria
|March 11, 2024
Summary
Extracellular vesicles (EVs) show promise as Alzheimer's disease (AD) biomarkers. Neuron-derived EVs contain AD proteins like amyloid beta, aiding early diagnosis and monitoring.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Extracellular vesicles (EVs) mediate cell signaling in the central nervous system (CNS).
- Alzheimer's disease (AD) is a neurodegenerative disorder involving cognitive decline and neuronal death.
- EVs are implicated in normal CNS function and AD pathogenesis.
Purpose of the Study:
- To investigate the role of EVs as potential biomarkers for Alzheimer's disease (AD).
- To analyze the composition of EVs in the context of AD pathology.
- To explore the diagnostic and monitoring potential of EVs in AD.
Main Methods:
- Analysis of EVs derived from neurons, astrocytes, and neuron precursor cells in AD.
- Detection of AD-associated proteins, including amyloid beta (Aß) and tau, within neuron-derived EVs.
- Isolation and quantification of neuron-derived EVs from plasma samples.
Main Results:
- EVs from various CNS cell types show altered quantity and composition in AD.
- Neuron-derived EVs contain key AD proteins such as amyloid beta (Aß) and tau.
- Elevated Aß levels in plasma-derived neuron-derived EVs correlate with AD and mild cognitive impairment, suggesting early biomarker potential.
Conclusions:
- EVs, particularly neuron-derived ones, show significant potential as biomarkers for early AD diagnosis and disease progression monitoring.
- Further research is needed to validate EV-based biomarkers and explore therapeutic applications.
- EVs represent a promising avenue for understanding and managing Alzheimer's disease.
More Related Videos
07:55Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
421
10:09Characterization of Immune Cell-derived Extracellular Vesicles and Studying Functional Impact on Cell Environment
Published on: June 2, 2020
6.9K
Related Concept Videos
01:36Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K
01:26Alzheimer's Disease: Overview
481
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
481
01:23Role of Neurotransmitters in Memory
549
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
549
01:22Alzheimer's Disease: Treatment
188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
01:38Intralumenal Vesicles and Multivesicular Bodies
3.5K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
3.5K
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K